Skip to content
Open access

Nitrosoamine Impurities: Current Status, Challenges and Future Perspectives

Sep 2026 · International Journal Of Recent Trends In Multidisciplinary Research · 0 citations

TL;DR

Nitrosamines are zwitterionic resonance structures which are bioactivated by cytochrome P450 into reactive diazonium ions, which form carcinogenic DNA adducts, especially O6-methylguanine, leading to mutations and epigenetic silencing of tumour suppressor genes.

Abstract

N-nitrosamine (NA) impurities have emerged as a critical safety concern in pharmaceutical manufacturing since the 2018 discovery of N-nitrosodimethylamine (NDMA) contamination in valsartan, which triggered global recalls and revealed similar issues in metformin, ranitidine, and rifampicin. Classified as Class 1 mutagenic carcinogens under ICH M7(R1) and Group 2A carcinogens by IARC, these compounds form through nitrosation reactions between secondary/tertiary amines and nitrosating agents. Contamination can arise from a number of sources including API synthesis (solvent degradation, azide quenching in sartan manufacture), excipient-drug interactions leading to complex nitrosamine drug substance-related impurities (NDSRIs), packaging materials (rubber components, blister packs), environmental water treatment processes, dietary sources (cured meats, tobacco) and endogenous gastric formation. Nitrosamines are zwitterionic resonance structures which are bioactivated by cytochrome P450 into reactive diazonium ions, which form carcinogenic DNA adducts, especially O6-methylguanine, leading to mutations and epigenetic silencing of tumour suppressor genes. Regulatory agencies (FDA, EMA, WHO) have adopted the Carcinogenic Potency Categorisation Approach (CPCA) in which compounds are placed in five potency categories with allowable intakes of 18 to 1500 ng/day with required risk assessment, confirmatory testing and remediation. Detection is carried out using very sensitive GC-MS/MS and LC-MS/MS platforms capable of quantifying contaminants at parts per billion levels and with rigorous sample preparation using nitrite scavengers to prevent artifactual nitrosation. Despite regulatory progress, major gaps remain in the toxicological characterisation, human-specific ADME data, and low-dose combined exposure effects of NDSRIs. Continued research, in silico prediction, green chemistry strategies, and international regulatory harmonisation are needed to protect the integrity of the drug supply and patient safety.

Read PDF

Similar papers

Review Open access Sep 2026

Nitrosamine Drug-Substance-Related Impurities (NDSRIs) in Pharmaceuticals: Formation Chemistry, Mechanistic Pathways, Analytical Characterization, Risk Assessment, Mitigation Strategies and Regulatory Perspectives

Nitrosamine drug-substance-related impurities (NDSRIs) have emerged as a distinctive pharmaceutical-quality challenge because their formation is governed by an intersection of drug-substance structure, nitrosating chemistry, formulation composition, manufacturing conditions, storage environment, and degradation pathway...

D. Satyanarayana, K. Mamatha, N. Amulya et al. · 1 citation
Review Aug 2026

EXPLORING NITROSAMINES: NITROSATION PATHWAY, ROOT CAUSES AND MITIGATION STRATEGIES

Nitrosamine impurities, classified as human carcinogens, have been detected in pharmaceutical drugs over the past several years. They are distinguished by the presence of the nitroso functional group and may develop under numerous conditions, including manufacturing and shelf life. Metabolic activation of nitrosamines...

Sharma S. S. M. Sonti, B. N. Nalluri · 0 citations
Review Open access Oct 2026

Risk-Based Determination of Analytical Sensitivity (LOQ) for Nitrosamine Impurities Using Acceptable Intake Limits

N-nitrosamine impurities found in the global pharmaceutical supply chain have forced an urgent transformation in the development of risk-based analytical monitoring and advanced quality control standards. The pivotal 2018 finding of the compound N-nitrosodimethylamine in the "sartan" drug class prompted the transition...

Santosh Bhende, A. Phatak, P. Chaudhari · 0 citations
Open access Aug 2026

Evaluation of Mutagenic Potential of Nitrosamines Using the Enhanced Ames Test with Hamster Liver S9 Activation

Nitrosamines (NAs) and Nitrosamine Drug Substance-Related Impurities (NDSRIs) have recently drawn significant attention because of their strong links to cancer and genetic damage. The standard Ames test, described in Organisation for Economic Co-operation and Development (OECD) Guideline 471, is widely used to assess...

S. Kadam, Aditya Hajare · 0 citations
Review Sep 2026

Nitrite-Driven Nitrosamine Formation in Pharmaceutical Systems: A Water-Mediated Risk Framework and Control Strategies

N-nitrosamines are genotoxic impurities whose detection in several marketed medicines has raised major safety concerns for pharmaceutical systems. They form when nitrosating agents - particularly nitrite - react with amine precursors under favourable physicochemical conditions. This review examines nitrite-driven nitro...

Santosh Bhende, A. Phatak, P. Chaudhari · 0 citations
Review Open access Sep 2026

Comparative Evaluation of Nitrosamine Impurity Control Strategies in USFDA, EMA, and WHO Pharmaceutical Submissions

Nitrosamine impurities are of significant concern to the pharmaceutical industry because of their genotoxic and carcinogenic effects. They are formed during the manufacturing, storage, and/or packaging of APIs and/or drug products owing to the nitrosation reactions of amines with nitrosating reagents. The detection of...

S. K, Immaculate Sherlin Sheridon Vaz, R. S. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.